Eflapegrastim

Drug Profile

Eflapegrastim

Alternative Names: Granulocyte colony-stimulating factor long-acting - Hanmi Pharmaceutical/Spectrum; Granulocyte colony-stimulating factor long-acting - Spectrum Pharmaceuticals; HM-10460A; HNK-460; LAPS-GCSF; Long-acting G-CSF analogue; ROLONTIS; SPI-2012

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Hanmi Pharmaceutical
  • Developer Hanmi Pharmaceutical; Spectrum Pharmaceuticals
  • Class Chemoprotectants; Granulocyte colony-stimulating factors; Immunoglobulin Fc fragments; Polyethylene glycols; Small molecules
  • Mechanism of Action Granulocyte colony stimulating factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Neutropenia

Most Recent Events

  • 03 Nov 2016 Spectrum Pharmaceuticals plans a phase III trial for Neutropenia (Chemotherapy-induced) in Europe
  • 01 Nov 2016 Spectrum Pharmaceuticals plans the phase III RECOVER trial for Neutropenia (Chemotherapy-induced) in USA (SC) (NCT02953340)
  • 10 Aug 2016 Spectrum Pharmaceuticals announces intention to submit BLA to US FDA in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top